SV2009002900A - Diarilurea para el tratamiento de hipertension pulmonar - Google Patents

Diarilurea para el tratamiento de hipertension pulmonar

Info

Publication number
SV2009002900A
SV2009002900A SV2008002900A SV2008002900A SV2009002900A SV 2009002900 A SV2009002900 A SV 2009002900A SV 2008002900 A SV2008002900 A SV 2008002900A SV 2008002900 A SV2008002900 A SV 2008002900A SV 2009002900 A SV2009002900 A SV 2009002900A
Authority
SV
El Salvador
Prior art keywords
treatment
pulmonary hypertension
diarilure
trifluorometilfenil
fluorophenophylophylopenophype
Prior art date
Application number
SV2008002900A
Other languages
English (en)
Spanish (es)
Inventor
Peter Sandner
Hanna Tinel
Joachim Hutter
Bernd Riedl
Martina Klein
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of SV2009002900A publication Critical patent/SV2009002900A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SV2008002900A 2005-11-10 2008-05-06 Diarilurea para el tratamiento de hipertension pulmonar SV2009002900A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14

Publications (1)

Publication Number Publication Date
SV2009002900A true SV2009002900A (es) 2009-04-28

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2008002900A SV2009002900A (es) 2005-11-10 2008-05-06 Diarilurea para el tratamiento de hipertension pulmonar

Country Status (18)

Country Link
US (1) US20100035888A1 (https=)
EP (1) EP1948170A1 (https=)
JP (1) JP5084736B2 (https=)
KR (1) KR20080067000A (https=)
AR (1) AR057849A1 (https=)
AU (1) AU2006312714A1 (https=)
BR (1) BRPI0618522A2 (https=)
CA (1) CA2628849A1 (https=)
CR (1) CR9953A (https=)
EC (1) ECSP088430A (https=)
GT (1) GT200800058A (https=)
IL (1) IL191178A0 (https=)
NO (1) NO20082498L (https=)
PE (1) PE20070806A1 (https=)
SV (1) SV2009002900A (https=)
TW (1) TW200733961A (https=)
UY (1) UY29903A1 (https=)
WO (1) WO2007054216A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158985B1 (en) * 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
AU2004212633B2 (en) * 2003-02-21 2010-12-09 ResMed Pty Ltd Nasal assembly
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
DK1797038T3 (da) * 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2675980C (en) * 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
JP2011525503A (ja) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全を処置するためのジアリールウレア
CN103079567A (zh) * 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
GB2503181A (en) * 2011-03-14 2013-12-18 Cellworks Res India Private Ltd Compositions, process of preparation of said compositions and method of treating inflammatory diseases
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7888341B2 (en) * 2002-04-10 2011-02-15 The United States Of America As Represented By The Department Of Veterans Affairs Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EP1850852A4 (en) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE

Also Published As

Publication number Publication date
WO2007054216A1 (en) 2007-05-18
KR20080067000A (ko) 2008-07-17
AU2006312714A1 (en) 2007-05-18
PE20070806A1 (es) 2007-09-29
CA2628849A1 (en) 2007-05-18
ECSP088430A (es) 2008-07-30
JP5084736B2 (ja) 2012-11-28
TW200733961A (en) 2007-09-16
AR057849A1 (es) 2007-12-19
BRPI0618522A2 (pt) 2011-09-06
EP1948170A1 (en) 2008-07-30
NO20082498L (no) 2008-08-07
IL191178A0 (en) 2009-08-03
UY29903A1 (es) 2007-06-29
GT200800058A (es) 2010-02-23
US20100035888A1 (en) 2010-02-11
JP2009514910A (ja) 2009-04-09
CR9953A (es) 2008-10-08

Similar Documents

Publication Publication Date Title
SV2009002900A (es) Diarilurea para el tratamiento de hipertension pulmonar
ECSP088429A (es) Diarilureas para el tratamiento de la hipertensión pulmonar
PT1485080E (pt) Utilização de adapaleno para o tratamento de desordens dermatológicas
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
SV2006002134A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
CO6150162A2 (es) Pirrolopirimidinas para composiciones farmaceuticas
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
CL2007003874A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
BRPI0713306A8 (pt) Composição farmacêutica compreendendo amlodipina e losartan
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
NO20076405L (no) Anvendelse av 24-nor-UDCA
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
CL2007003189A1 (es) Compuestos derivados de indol y benzofurano; composicion farmaceutica; y uso para el tratamiento o la prevencion de la enfermedad de alzheimer.
BR112012021445A2 (pt) formulação farmacêutica ou neutracêutica.
BRPI0607003A2 (pt) forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
PA8787001A1 (es) " derivados de macrolactona"
MX2009008548A (es) Formulaciones de olopatadina para administracion nasal topica.

Legal Events

Date Code Title Description
FD Lapse